CN111529481B - 用于治疗视觉障碍的组合物和方法 - Google Patents

用于治疗视觉障碍的组合物和方法 Download PDF

Info

Publication number
CN111529481B
CN111529481B CN202010136027.9A CN202010136027A CN111529481B CN 111529481 B CN111529481 B CN 111529481B CN 202010136027 A CN202010136027 A CN 202010136027A CN 111529481 B CN111529481 B CN 111529481B
Authority
CN
China
Prior art keywords
pharmaceutical composition
lanosterol
formulated
ophthalmic
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010136027.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111529481A (zh
Inventor
张康
侯睿
蔡惠民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Kangrui Biological Pharmaceutical Technology Co ltd
University of California, San Diego
Original Assignee
Guangzhou Kangrui Biological Pharmaceutical Technology Co ltd
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Kangrui Biological Pharmaceutical Technology Co ltd, University of California, San Diego filed Critical Guangzhou Kangrui Biological Pharmaceutical Technology Co ltd
Priority to CN202010136027.9A priority Critical patent/CN111529481B/zh
Publication of CN111529481A publication Critical patent/CN111529481A/zh
Application granted granted Critical
Publication of CN111529481B publication Critical patent/CN111529481B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN202010136027.9A 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法 Active CN111529481B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010136027.9A CN111529481B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462040721P 2014-08-22 2014-08-22
US62/040,721 2014-08-22
US201562194120P 2015-07-17 2015-07-17
US62/194,120 2015-07-17
PCT/US2015/046453 WO2016029199A1 (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders
CN202010136027.9A CN111529481B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法
CN201580057679.0A CN107206009B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580057679.0A Division CN107206009B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法

Publications (2)

Publication Number Publication Date
CN111529481A CN111529481A (zh) 2020-08-14
CN111529481B true CN111529481B (zh) 2023-09-15

Family

ID=55351326

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010136027.9A Active CN111529481B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法
CN201580057679.0A Active CN107206009B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580057679.0A Active CN107206009B (zh) 2014-08-22 2015-08-24 用于治疗视觉障碍的组合物和方法

Country Status (13)

Country Link
US (1) US10471076B2 (enExample)
EP (1) EP3182977B1 (enExample)
JP (1) JP6706020B2 (enExample)
KR (1) KR20170048426A (enExample)
CN (2) CN111529481B (enExample)
AU (1) AU2015305199A1 (enExample)
BR (1) BR112017003529A2 (enExample)
CA (1) CA2958868A1 (enExample)
EA (1) EA035798B1 (enExample)
HK (1) HK1243325A1 (enExample)
MX (1) MX2017002374A (enExample)
SG (1) SG11201701377YA (enExample)
WO (1) WO2016029199A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958868A1 (en) 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders
WO2017019808A1 (en) * 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
CN109364020B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
ES2890667T3 (es) * 2017-01-25 2022-01-21 Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd Compuesto de profármaco de lanosterol y su uso del mismo
GB2581656A (en) * 2017-11-17 2020-08-26 Piraee Mahmood Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
CN109985052A (zh) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 三萜类化合物的新用途
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
JP7046266B2 (ja) * 2018-07-25 2022-04-01 グアンジョウ オクスン オフサルミク バイオテクノロジー カンパニーリミテッド ラノステロールプロドラッグ化合物の結晶形及びその使用
US12329763B2 (en) * 2019-03-04 2025-06-17 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Composition of lanosterol prodrug compound, preparation method therefor and use thereof
MX2021009520A (es) 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
CN115737654B (zh) 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN116570706A (zh) * 2022-02-09 2023-08-11 上海瑞吉康生物医药有限公司 使用多肽治疗白内障的方法
WO2023198192A1 (zh) * 2022-04-15 2023-10-19 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗老花眼的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059357A2 (en) * 2004-12-03 2006-06-08 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization
CN101959503A (zh) * 2008-02-29 2011-01-26 财团法人名古屋产业科学研究所 眼后节到达用脂质体和眼后节疾病用医药组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
RU2476226C2 (ru) * 2008-08-05 2013-02-27 Амазония Фитомедикаментос Лтда Фармацевтические применения ланоста-8,24-диен-3-олов
CA2878946A1 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
EP2890363A1 (en) * 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
CA2958868A1 (en) 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059357A2 (en) * 2004-12-03 2006-06-08 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization
CN101959503A (zh) * 2008-02-29 2011-01-26 财团法人名古屋产业科学研究所 眼后节到达用脂质体和眼后节疾病用医药组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Effectiveness of novel chemical inhibitors of staphylococcus aureus alpha-toxin in vitro and in vivo;Anastasia C.Weeks,et al.;《Investigative ophthalmology & visual science》;20110430;第52卷(第14期);摘要 *

Also Published As

Publication number Publication date
JP6706020B2 (ja) 2020-06-03
HK1243325A1 (zh) 2018-07-13
US10471076B2 (en) 2019-11-12
EA201790397A1 (ru) 2017-08-31
JP2017525769A (ja) 2017-09-07
EP3182977A4 (en) 2018-04-11
MX2017002374A (es) 2017-09-15
SG11201701377YA (en) 2017-03-30
EA035798B1 (ru) 2020-08-12
KR20170048426A (ko) 2017-05-08
CN107206009A (zh) 2017-09-26
WO2016029199A1 (en) 2016-02-25
BR112017003529A2 (pt) 2019-08-20
CN111529481A (zh) 2020-08-14
EP3182977A1 (en) 2017-06-28
AU2015305199A1 (en) 2017-04-13
CA2958868A1 (en) 2016-02-25
CN107206009B (zh) 2020-03-27
US20170065617A1 (en) 2017-03-09
EP3182977B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
CN107206009B (zh) 用于治疗视觉障碍的组合物和方法
JP6209791B2 (ja) 白内障を処置するためのα−クリスタリン凝集の阻害剤
US20190117675A1 (en) Compositions And Methods To Treat And/Or Prevent Vision Disorders Of The Lens Of The Eye
JP2021512906A (ja) 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
Liang et al. miR-328-3p affects axial length via multiple routes and anti-miR-328-3p possesses a potential to control myopia progression
Sin et al. A spontaneous nonhuman primate model of myopic foveoschisis
WO2026080585A1 (en) Treatment of retinal degeneration
US20200140500A1 (en) High throughput methods, protein inhibitors, and uses thereof
JP7849841B2 (ja) リソソーム関連膜タンパク質標的化化合物及びその使用
Long et al. Advances in RPGR gene therapy for X-linked retinitis pigmentosa: From preclinical insights to clinical application
US20200138832A1 (en) Compounds and prodrugs thereof for the treatment of ophthalmic disease
HK40011572A (en) Non-surgical method of treatment for cataract
HK1212271B (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PP01 Preservation of patent right

Effective date of registration: 20250929

Granted publication date: 20230915

PP01 Preservation of patent right